Elizabeth Anderson

Summary

Affiliation: University of Manchester
Country: UK

Publications

  1. pmc The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis
    Elizabeth Anderson
    Tumour Biochemistry Laboratory, Christie Hospital NHS Trust, Manchester, UK
    Breast Cancer Res 4:197-201. 2002
  2. ncbi request reprint Cellular homeostasis and the breast
    Elizabeth Anderson
    Tumour Biochemistry Laboratory, Clinical Research Department, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Maturitas 48:S13-7. 2004
  3. ncbi request reprint Steroid receptors and cell cycle in normal mammary epithelium
    Elizabeth Anderson
    Christie Hospital NHS Trust, Manchester, UK
    J Mammary Gland Biol Neoplasia 9:3-13. 2004
  4. ncbi request reprint Estrogen responsiveness and control of normal human breast proliferation
    E Anderson
    Clinical Research Department, Christie Hospital NHS Trust, Manchester
    J Mammary Gland Biol Neoplasia 3:23-35. 1998
  5. pmc Epithelial stem cells in the mammary gland: casting light into dark corners
    E Anderson
    Tumour Biochemistry Laboratory, Clinical Research Department, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, England
    Breast Cancer Res 1:11-3. 1999
  6. ncbi request reprint A putative human breast stem cell population is enriched for steroid receptor-positive cells
    Robert B Clarke
    Breast Biology Group, Cancer Research UK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK
    Dev Biol 277:443-56. 2005
  7. pmc Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo
    Fredrik Warnberg
    Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
    Breast Cancer Res 8:R21. 2006
  8. pmc Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity
    Sacha J Howell
    Breast Biology Group, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK
    Breast Cancer Res 10:R68. 2008
  9. ncbi request reprint Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen
    Nigel J Bundred
    Department of Surgery, South Manchester University Hospital Education and Research Centre, UK
    Anticancer Res 22:2317-9. 2002
  10. pmc Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone
    R B Clarke
    Clinical Research Department, Christie Hospital NHS Trust, Withington, Manchester, UK
    Br J Cancer 75:251-7. 1997

Collaborators

Detail Information

Publications26

  1. pmc The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis
    Elizabeth Anderson
    Tumour Biochemistry Laboratory, Christie Hospital NHS Trust, Manchester, UK
    Breast Cancer Res 4:197-201. 2002
    ....
  2. ncbi request reprint Cellular homeostasis and the breast
    Elizabeth Anderson
    Tumour Biochemistry Laboratory, Clinical Research Department, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Maturitas 48:S13-7. 2004
    ..Whatever the mechanism, the proliferative effects of progesterone on the post-menopausal breast have implications for the use of HRT...
  3. ncbi request reprint Steroid receptors and cell cycle in normal mammary epithelium
    Elizabeth Anderson
    Christie Hospital NHS Trust, Manchester, UK
    J Mammary Gland Biol Neoplasia 9:3-13. 2004
    ..Answering these questions could greatly increase our understanding of the factors controlling mammary gland development and the processes leading to cancer formation...
  4. ncbi request reprint Estrogen responsiveness and control of normal human breast proliferation
    E Anderson
    Clinical Research Department, Christie Hospital NHS Trust, Manchester
    J Mammary Gland Biol Neoplasia 3:23-35. 1998
    ..Finally, study of the paracrine mechanisms of growth control in the normal human breast may provide new, more specific, therapeutic targets for breast cancer prevention...
  5. pmc Epithelial stem cells in the mammary gland: casting light into dark corners
    E Anderson
    Tumour Biochemistry Laboratory, Clinical Research Department, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, England
    Breast Cancer Res 1:11-3. 1999
    ..Now, studies carried out by Kordon and Smith at the National Cancer Institute have pointed the way toward a new understanding of mammary stem cells and their progeny...
  6. ncbi request reprint A putative human breast stem cell population is enriched for steroid receptor-positive cells
    Robert B Clarke
    Breast Biology Group, Cancer Research UK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester M20 4BX, UK
    Dev Biol 277:443-56. 2005
    ..The data suggest a model where scattered steroid receptor-positive cells are stem cells that self-renew through asymmetric cell division and generate patches of transit amplifying and differentiated cells...
  7. pmc Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo
    Fredrik Warnberg
    Breast Biology Group, Christie Hospital NHS Trust, Manchester, UK
    Breast Cancer Res 8:R21. 2006
    ..Effects on tumour xenografts and human ductal carcinoma in situ (DCIS) of the breast in a xenograft mouse model were also tested...
  8. pmc Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity
    Sacha J Howell
    Breast Biology Group, Paterson Institute for Cancer Research, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK
    Breast Cancer Res 10:R68. 2008
    ..We examined the effects of the 'pure' prolactin receptor antagonist Delta1-9-G129R-hPrl (Delta1-9) on the breast cancer cell number and clonogenicity, alone and in combination with chemotherapy...
  9. ncbi request reprint Fulvestrant, an estrogen receptor downregulator, reduces cell turnover index more effectively than tamoxifen
    Nigel J Bundred
    Department of Surgery, South Manchester University Hospital Education and Research Centre, UK
    Anticancer Res 22:2317-9. 2002
    ..This study was performed to determine whether drug action on breast tumours could also be analysed using a cell turnover index (CTI), a composite measurement of both proliferation and apoptosis...
  10. pmc Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone
    R B Clarke
    Clinical Research Department, Christie Hospital NHS Trust, Withington, Manchester, UK
    Br J Cancer 75:251-7. 1997
    ..The results are consistent with the suggestion that E2 may act to stimulate proliferation indirectly via a paracrine mechanism involving IGFs in normal as well as malignant human breast epithelial cells...
  11. ncbi request reprint Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression
    R B Clarke
    Clinical Research Department, Christie Hospital NHS Trust, Withington, Manchester, UK
    Breast Cancer Res Treat 45:121-33. 1997
    ....
  12. pmc Effect of tamoxifen on Ki67 labelling index in human breast tumours and its relationship to oestrogen and progesterone receptor status
    R B Clarke
    Clinical Research Dept, Christie Hospital NHS Trust, Withington, Manchester
    Br J Cancer 67:606-11. 1993
    ..These data indicate that staining with the Ki67 antibody may be useful in monitoring response to anti-oestrogen therapy...
  13. ncbi request reprint Platinum agents in the treatment of osteosarcoma: efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines
    H Robson
    Tumour Biochemistry Laboratory, Clinical Research Department, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK
    Med Pediatr Oncol 39:573-80. 2002
    ..Studies evaluating the role of combination CT containing CBDCA vs. cDDP have demonstrated differing results depending on the tumor type tested and its role in the treatment of osteosarcoma has yet to be clarified...
  14. ncbi request reprint Dissociation between steroid receptor expression and cell proliferation in the human breast
    R B Clarke
    Clinical Research Department, University of Manchester Christie Hospital National Health Service Trust, United Kingdom
    Cancer Res 57:4987-91. 1997
    ..This organization may be disrupted in some tumors...
  15. ncbi request reprint Regulation of human breast epithelial stem cells
    Robert B Clarke
    Breast Biology Group, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Wilmslow Road, Withington, Manchester, UK
    Cell Prolif 36:45-58. 2003
    ..ERalpha/PR+ breast cancers exhibit loss of the two key regulators of asymmetric cell division, Musashi-1 and Notch-1 and thus may arise from symmetric division of the ERalpha/PR+ stem cell...
  16. ncbi request reprint Steroid receptors in human breast cancer
    Robert B Clarke
    CR UK Department of Medical Oncology, Christie Hospital, Manchester, UK
    Trends Endocrinol Metab 15:316-23. 2004
    ..These interactions might explain resistance to endocrine treatments and offer solutions in terms of novel therapeutic targets...
  17. ncbi request reprint Written report of presented lectures: endocrine treatment and prevention of breast and gynaecological cancers. The scientific basis of endocrine prevention
    A Howell
    CRC Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Manchester, UK
    Eur J Cancer 38:S13-4. 2002
  18. pmc Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
    M Bramley
    Department of Surgery, Christie Hospital NHS Trust, Manchester M20 4BX, USA
    Br J Cancer 94:1021-8. 2006
    ..We conclude that early anti-oestrogen treatment should prevent breast cancer in very high-risk women...
  19. ncbi request reprint Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    A Howell
    CRC Department of Medical Oncology, Christie Hospital NHS Trust, M20 4BX, Manchester, UK
    J Steroid Biochem Mol Biol 79:227-37. 2001
    ..These data and the newer treatments available indicate a need to re-think our general approach to endocrine therapy and endocrine prevention...
  20. doi request reprint Risk reducing mastectomy: outcomes in 10 European centres
    D G R Evans
    Central Manchester and Manchester Children s University Hospitals NHS Trust, St Mary s Hospital, Manchester, M13 0JH, UK
    J Med Genet 46:254-8. 2009
    ..Increasingly women at high risk of breast cancer are opting for risk reducing surgery. The aim of this study was to assess the effectiveness of this approach in women at high risk in both carriers and non-carriers of BRCA1/2...
  21. ncbi request reprint Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma
    Ramachandran Prasad
    Department of Surgery, University Hospital of South Manchester, Manchester, United Kingdom
    Cancer 98:2539-46. 2003
    ..The goal of rhe current study was to determine the short-term effect of HRT withdrawal on invasive breast carcinoma using biologic surrogate markers of tumor response...
  22. ncbi request reprint Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells
    Matthew H Herynk
    Breast Center, Baylor College of Medicine, One Baylor Plaza, Mailstop 600, Houston, TX 77030, USA
    Mol Cancer Ther 5:3023-31. 2006
    ..Here, we show that c-Src inhibition is blocked by estrogen signaling; thus, the therapeutic use of c-Src inhibitors may require inhibition of ERalpha in estrogen-dependent breast cancer...
  23. ncbi request reprint Unblinding of trial participants to their treatment allocation: lessons from the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
    Eleanor M Dinnett
    Clinical Trials Unit, Glasgow Royal Infirmary, Glasgow, UK
    Clin Trials 2:254-9. 2005
    ..Here we document our experiences of unblinding the 2520 Scottish participants in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)...
  24. ncbi request reprint Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries
    Anthony Rhodes
    UK NEQAS ICC, The Department of Histopathology, University College London Medical School, England
    Am J Clin Pathol 118:408-17. 2002
    ....
  25. ncbi request reprint A dual, non-redundant, role for LIF as a regulator of development and STAT3-mediated cell death in mammary gland
    Ekaterini A Kritikou
    Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, UK
    Development 130:3459-68. 2003
    ..Inhibition of LIF-mediated ERK1/2 phosphorylation potentiates the proapoptotic effects of STAT3. LIF therefore signals alternately through ERK1/2, then STAT3, to regulate mammary growth and apoptosis...